Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ramon Sanchez

Neurology Atlanta, GA Medical Doctor

NPI 1487678116 CMS profile 22180

5730 Glenridge Dr Ste 220, Atlanta, GA 30328

Open in the dashboard

General payments

$8,044

406 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ramon Sanchez of Atlanta, GA is reported in the CMS Open Payments database as having received $8,044 across 406 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $804 39
2024 General $710 28
2023 General $1,333 61
2022 General $1,811 97
2021 General $1,592 89
2020 General $492 26
2019 General $1,303 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ramon Sanchez
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Ramon Sanchez were reported at $804. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Ramon Sanchez Neurology median Middle half National median
2019 $1,303 $474 $118–$2,177 $163
2020 $492 $367 $82–$2,309 $114
2021 $1,592 $438 $104–$2,547 $132
2022 $1,811 $442 $103–$2,388 $149
2023 $1,333 $464 $119–$2,312 $160
2024 $710 $468 $119–$2,323 $164
2025 $804 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sunovion Pharmaceuticals Inc. $1,034 42 payments
  2. Eisai Inc. $614 31 payments
  3. SK Life Science, Inc. $541 26 payments
  4. AbbVie, Inc. $540 44 payments
  5. Lilly USA, LLC $478 24 payments
  6. UCB, Inc. $324 15 payments
  7. Sumitomo Pharma America, Inc. $310 13 payments
  8. Pfizer Inc. $296 13 payments
  9. Catalyst Pharmaceuticals, Inc. $287 13 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $273 16 payments
  11. Other $3,346 169 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,044 406 payments
Products named General payments · program years 2019–2025
  1. APTIOM $1,300 53 payments
  2. Fycompa Neurology $576 29 payments
  3. NURTEC ODT Primary Care $483 29 payments
  4. NURTEC ODT Pain $296 13 payments
  5. FYCOMPA Neurology $287 13 payments
  6. NUPLAZID $243 11 payments
  7. EMGALITY $230 13 payments
  8. UBRELVY $229 19 payments
  9. QULIPTA $220 20 payments
  10. VALTOCO $212 8 payments
  11. Other $4,258 215 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 72 drugs

Part D claims

3,293

Median for Neurology: 833

Drug cost

$281,992

Median for Neurology: $202,670

Branded share of claims

23.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aptiom Eslicarbazepine Acetate Brand 32 $107,694
Nucynta Tapentadol Hcl Brand 17 $34,236
Neupro Rotigotine Brand 26 $24,813
Trileptal Oxcarbazepine Brand 14 $19,402
Xtampza Er Oxycodone Myristate Brand 15 $11,889
Memantine Hcl Er Memantine Hcl Brand 97 $9,426
Aimovig Autoinjector Erenumab-Aooe Brand 12 $8,540
Oxymorphone Hcl Er Oxymorphone Hcl Brand 12 $5,925
Fentanyl Generic 13 $4,040
Rivastigmine Generic 31 $3,347

The 10 drugs with the highest cost, of 72 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$87,987

Medicare's payments for the services billed

Medicare patients

142

Average age 74

Services billed

569

89 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 30%
Depression 29%
Alzheimer's or dementia 25%
Diabetes 24%
Chronic kidney disease 23%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Gocovri
  • US WorldMeds, LLC $148
$148 — —
AMYVID
  • Lilly USA, LLC $86
$86 — —
NURTEC ODT
  • PFIZER INC. $56
$56 — —
Leqembi
  • Biogen, Inc. $24
  • Eisai Inc. $22
$47 — —
KISUNLA
  • Lilly USA, LLC $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

406 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record